Introduction
============

Candiduria, defined as various Candida species found in the urine, is becoming an increasingly serious problem in hospitalized patients. Antibiotics, corticosteroids, immunosuppressive agents, and urinary catheters, all of which are used extensively in clinical practice, are regarded as possible risk factors ([@ref-9]). The presence of Candida in urine does not always signify a fungal urinary tract infection (UTI) and may derive from colonization or sample contamination ([@ref-14]). Nevertheless, candiduria could be considered a valuable clue to the diagnosis and treatment of fungal UTIs, especially in high-risk hospitalized patients. Numerous studies in experimental animals and clinical observations have indicated that the kidney consistently acts as the main fungus-bearing organ during candida infection ([@ref-4]; [@ref-32]; [@ref-34]). In severely ill patients, candiduria has been considered to be significantly associated with disseminated candidiasis ([@ref-8]; [@ref-12]; [@ref-3]). In surgical intensive care unit (ICU) settings, candiduria has been proved to be an independent factor associated with mortality ([@ref-22]).

For most clinical laboratories, urine culture is the first-line technique to determine candiduria. This conventional manual assay is time consuming, labor intensive and unsuitable for large-scale screening and investigation purposes. For a long time, flow cytometry was regarded as a useful tool for yeast characterization ([@ref-13]). By utilizing fluorescent staining and flow cytometric technology, the Sysmex UF-1000i system measures each detected formed element, including fungi in urine, simply and efficiently. Several studies ([@ref-11]; [@ref-21]; [@ref-23]) have supported the reliability of an automatic urine analysis system for bacteria and yeast-like cell (YLC) detection.

Previous epidemiological studies of candiduria ([@ref-1]; [@ref-18]; [@ref-26]) have been based on culture assay and limited to small study populations. Hence, further data collected by automated systems from a large target population are necessary for more comprehensive understanding of candiduria in hospitalized patients. The aim of this study was to collect epidemiological data on candiduria with the Sysmex UF-1000i urine flow cytometry analysis system and to assess the incidence of candiduria in hospitalized patients. The risk factors and outcomes of ICU candiduria patients were also investigated in this study.

Materials & Methods
===================

Study population
----------------

This study was conducted between September 1, 2016, and August 31, 2017, in Bethune International Peace Hospital of PLA and was approved by the local research ethics committee (approval number: 2016-KY-034). We studied 45,371 urine samples collected from 31,648 hospitalized patients, including 17,840 males and 13,808 females. The enrolled patients were aged 1 day to 106 years old with a median age of 56 years. Samples from infants younger than 3 years accounted for 8.86% of the total number of samples. Clinical data, including age, gender, primary diagnosis, risk factors (e.g., presence of catheter, antibiotics, parenteral nutrition, immunosuppressive treatment, renal failure, abdominal surgery, diabetes and malignancy) and prognosis, were obtained from medical records. For ICU patients, Acute Physiology and Chronic Health Evaluation (APACHE) II scores were used to evaluate ICU admission severity.

Patients were instructed on how to collect mid-stream urine before sample collection. For babies younger than 1 year, a sterile urine collection bag was applied according to the manufacturer's instructions. The samples were collected in the morning and were stored in a disposable sterile bottle with a screw lid. All samples were analyzed within 3 h after collection.

All urine samples received were examined with a Sysmex UF-1000i analysis system and the count of yeast-like cells (YLCs) was used as a candiduria marker ([@ref-11]). For patients who underwent repeated urine examinations, the maximum YLC count value was recorded.

Microbiology analysis
---------------------

To determine the performance of the Sysmex UF-1000i in detecting candiduria, a cross-sectional study was designed and conducted. A total of 203 YLC-positive and 127 negative samples were randomly chosen and subjected to microbiological analysis. Briefly, 0.01 ml of each urine sample was spread on a CHROMagar plate with a calibrated loop, and the culture plates were incubated aerobically at 35 °C for 48 h. The Candida species were identified based on growth color and colony shape and were further confirmed by the API 20C AUX Yeast Identification System (BioMerieux, Craponne, France). The determined level for quantitative cultures to be considered significant was 10^3^ CFU/ml (10 CFU/plate).

Statistical analysis
--------------------

The LOG YLC counts results of the culture-positive/negative groups are given as mean ± standard deviation (SD). The candiduria rate according to age groups, genders and wards were statistically compared using Fisher's exact test. Risk factors for ICU patients were assessing by logistic regression. Statistical analysis of YLC counts were performed with the Mann--Whitney test. A *P* value \< 0.05 was considered significant. Statistical analysis was performed using software GraphPad Prism 7.0 and SPSS 17.0. The characteristics of YLC for determining candiduria, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated.

Results
=======

YLC detection capacity of the Sysmex UF1000i and cutoff value determination
---------------------------------------------------------------------------

By microbiological culture assay, we isolated 132 strains of Candida species from 119 (119/203) YLC-positive samples and eight strains from eight (8/127) YLC-negative samples. [Table 1](#table-1){ref-type="table"} displays the prevalence of the 140 isolated Candida species strains, including 47 strains of *Candida glabrata*, 44 strains of *Candida tropicalis*, 34 strains of *Candida albicans*, six strains of *Candida krusei*, four strains of *Candida parapsilosis* and five strains of other species.
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###### The prevalence of candida species in the urine investigated by culture.

![](peerj-07-6935-g002)

  Candida species                                    No. (%) indentified[^a^](#table-1fn1){ref-type="fn"}
  -------------------------------------------------- ------------------------------------------------------
  *C. glabrata*                                      47 (33.6)
  *C. tropicalis*                                    44 (31.4)
  *C. albicans*                                      34 (24.3)
  *C. krusei*                                        6 (4.29)
  *C. parapsilosis*                                  4 (2.86)
  Other *C. spp*.[^b^](#table-1fn2){ref-type="fn"}   5 (3.57)

**Notes.**

13 patients had \>1 candida species isolated at baseline.

Includes *Candida guilliermondii* (2), *Candida lusitaniae* (1), *Saccharomyces cerevisiae* (1) and *Candida pseudotropicalis* (1).

[Figure 1A](#fig-1){ref-type="fig"} shows the YLC counts obtained from the YLC-positive samples. Compared to that of the culture-negative group, the YLC count (LOG n) of the culture-positive group was significantly higher (2.259 ± 0.067 VS 1.524 ± 0.052, *P* \< 0.001). The receiver operating characteristic curve (ROC) was utilized to evaluate the predictive ability of the Sysmex UF1000i YLC count to predict candiduria. The sensitivity and specificity were calculated based on a determined cutoff value of the ROC curve. As [Fig. 1B](#fig-1){ref-type="fig"} shows, the area under the curve (AUC) was 0.789 with a 95% confidence interval of 0.728--0.851. The Youden index (sensitivity + specificity − 1) was generated, and 84.6 YLCs/µL was determined as the best cutoff value. The sensitivity, specificity, PPV and NPV of the YLC counts to determine candiduria were 61.7%, 84.1%, 88.6% and 66.3%, respectively.

![Yeastlike cells (YLC) performance for screening candiduria.\
(A) For YLC positive samples, YLC count (LOG n) of culture positive samples is significantly higher than culture negative samples (*P* \< 0.001). The error bars represent the standard deviations; (B) The receiver operating characteristic curve (ROC) was utilized to determine the cutoff YLC value for candiduria identifying. The area under the curve (AUC) was 0.789 and the cutoff value was determined as 84.6 YLCs/µL.](peerj-07-6935-g001){#fig-1}

Characteristics of patients with candiduria
-------------------------------------------

For the investigated samples, 684 of 45,371 (1.51%) were determined to be positive, and 509 of 31,648 (1.61%) patients were considered candiduria-positive with a YLC cutoff value of 84.6 YLCs/µL.

[Table 2](#table-2){ref-type="table"} shows the age and gender distribution of the candiduria patients. The enrolled patients were divided into five age groups, and per-age maximum candiduria determination was displayed as follows: \<1 group (3.41%), followed by the 60 + (2.51%) and 18∼59 groups (1.06%). The 1∼6 (0.20%) and 7∼17 groups (0.54%) showed very low candiduria rates. Of the 509 positive patients, 235 were male, and 274 were female, and the candiduria occurrence rate was statistically higher in female patients than in male patients (*P* \< 0.001).
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###### Age and gender of 509 patients with candiduria.

![](peerj-07-6935-g003)

  Characteristic      Candiduria (*n* = 509)   Non-candiduria (*n* = 31,139)
  ------------------- ------------------------ -------------------------------
  Age, years, n (%)                            
  \<1                 49 (3.41)                1,387
  1∼6                 5 (0.20)                 2,553
  7∼17                7 (0.54)                 1,292
  18∼59               157 (1.06)               14,604
  60∼                 291 (2.51)               11,303
  Gender, n (%)                                
  Male                235 (1.32)               17,605
  Female              274 (1.98)               13,534

Underlying disease was recognized as the main factor for candiduria. [Table 3](#table-3){ref-type="table"} exhibits the ward distribution of the candiduria patients. Generally, candiduria rates in patients from internal medicine wards were more than two times higher than those of patients in the surgical wards (1.98% vs 0.94%, *P* \< 0.001). The ICU (22.89%), nephrology (7.06%), geriatrics (5.66%), NICU (3.66%), neurosurgery (2.94%), hematology (2.78%), oncology (2.60%) and respiratory (2.54%) wards were the leading wards for candiduria, with occurrence rates were significantly higher than the average rate (1.61%).
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###### Number of candiduria patients from different medical wards.
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  Ward[^a^](#table-3fn1){ref-type="fn"}   Candiduria, %   Non-candiduria   *P* value [^b^](#table-3fn2){ref-type="fn"}
  --------------------------------------- --------------- ---------------- ---------------------------------------------
  Internal medicine                       411 (1.98)      20,802           0.02[^\*^](#table-3fn3){ref-type="fn"}
  CCU                                     18 (1.38)       1,284            0.57
  Gynaecology                             10 (0.60)       1,654            0.0015[^\*^](#table-3fn3){ref-type="fn"}
  Infectious disease                      9 (1.74)        508              0.78
  Hepatology                              5 (0.62)        800              0.03[^\*^](#table-3fn3){ref-type="fn"}
  Pediatrics                              9 (0.33)        2,729            \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  NICU                                    42 (3.66)       1,104            \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Respiratory                             47 (2.54)       1,804            0.0016[^\*^](#table-3fn3){ref-type="fn"}
  Emergency                               2 (2.22)        88               0.66
  Geriatrics                              65 (5.66)       1,083            \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Endocrinology                           19 (1.58)       1,180            1.00
  Neurology                               12 (0.72)       1,656            0.0052[^\*^](#table-3fn3){ref-type="fn"}
  Nephrology                              68 (7.06)       895              \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Gastroenterology                        22 (1.68)       1,291            0.79
  Cardiovascular                          7 (0.30)        2,303            \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Hematology                              11 (2.78)       384              0.06
  Rheumatology                            8 (1.22)        649              0.46
  Oncology                                19 (2.60)       712              0.03[^\*^](#table-3fn3){ref-type="fn"}
  ICU                                     38 (22.89)      128              \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Surgery wards                           98 (0.94)       10,337           \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Hepatobiliary                           4 (0.65)        615              0.07
  ENT                                     11 (0.39)       2,793            \<0.0001[^\*^](#table-3fn3){ref-type="fn"}
  Orthopaedics                            13 (0.84)       1,530            0.02[^\*^](#table-3fn3){ref-type="fn"}
  Urology                                 17 (1.74)       961              0.70
  General surgery                         16 (0.87)       1,833            0.015[^\*^](#table-3fn3){ref-type="fn"}
  Neurosurgery                            19 (2.94)       627              0.0066[^\*^](#table-3fn3){ref-type="fn"}
  Vascular surgery                        7 (1.09)        637              0.32
  Cardiothoracic                          1 (0.26)        391              0.04[^\*^](#table-3fn3){ref-type="fn"}
  Ophthalmology                           4 (0.55)        726              0.02[^\*^](#table-3fn3){ref-type="fn"}
  Obstetrics                              6 (0.77)        774              0.07

**Notes.**

CCU, cardiac care unit; NICU, neonatal intensive care unit; ICU, intensive care unit; ENT, ear, nose and throat.

Compared with overall candiduria incidence rate (509/31648, 1.61%); *P* value \< 0.05 was considered significant.

*P* \< 0.05.

Risk factors and outcome of ICU candiduria patients
---------------------------------------------------

Subjects in this study included 166 patients from the ICU of our hospital, among whom 38 were identified as having candiduria (38/166, 22.89%). Previous reports showed high candiduria rates in ICU patients, and we further investigated the risk factors and outcomes of the ICU candiduria patients.

Among the several risk factors investigated, the presence of a catheter was found to be statistically significant by multi-factor logistic regression analysis (*P* \< 0.05, [Table 4](#table-4){ref-type="table"}). Other factors, including age \>60 years, antibiotic and immunosuppressive therapy, parenteral nutrition, abdominal surgery, diabetes, malignancy, renal failure and APACHE II scores were not found to be statistically significant.
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###### Risk factors and outcome for ICU candiduria patients.
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  Characteristic for ICU patients                 Candiduria (n, %)   Non-candiduria (n, %)   Single-factor logistic regression analysis   Multi-factor logistic regression analysis                                             
  ----------------------------------------------- ------------------- ----------------------- -------------------------------------------- ------------------------------------------- ----------------------------------------- -----------------------
  ***Risk factors***                                                                                                                                                                                                             
  APACHE II score (median, interquartile range)   17 (12--23)         13 (9--16)              0.001[^\*^](#table-4fn1){ref-type="fn"}      1.109 (1.047--1.175)                        0.774                                     0.932 (0.576--1.507)
  \>60 years                                      28 (73.68)          90 (70.31)              0.561                                        1.273 (0.564--2.870)                        0.911                                     1.051 (0.437--2.532)
  Presence of catheter                            22 (57.89)          41 (32.03)              0.004[^\*^](#table-4fn1){ref-type="fn"}      3.025 (1.437--6.369)                        0.006[^\*^](#table-4fn1){ref-type="fn"}   3.161 (1.385--7.212)
  Antibiotics                                     33 (86.84)          109 (85.16)             0.795                                        1.150 (0.399--3.318)                        0.633                                     0.749 (0.228--2.456)
  Parenteral nutrition                            23 (60.53)          69 (53.91)              0.665                                        1.176 (0.566--2.444)                        0.965                                     0.981 (0.417--2.308)
  Immunosuppressive treatment                     2 (5.26)            3 (2.34)                0.368                                        2.315 (0.372--14.390)                       0.883                                     1.192 (0.115--12.377)
  Abdominal surgery                               4 (10.52)           7 (5.47)                0.377                                        1.765 (0.501--6.216)                        0.366                                     1.902 (0.472--7.664)
  Renal failure                                   19 (50.0)           38 (29.69)              0.057                                        2.054 (0.980--4.303)                        0.077                                     2.203 (0.917--5.291)
  Diabetes                                        14 (36.84)          35 (27.34)              0.262                                        1.550 (0.721--3.332)                        0.473                                     1.372 (0.579--3.251)
  Malignancy                                      6 (15.79)           12 (9.38)               0.269                                        1.812 (0.631--5.207)                        0.098                                     3.348 (0.801--13.996)
  ***Outcome***                                                                                                                                                                                                                  
  Dead in hospital                                13 (34.21)          13 (10.16)              0.001[^\*^](#table-4fn1){ref-type="fn"}      4.600 (1.904--11.113)                       --                                        --
  Discharge                                       25 (65.79)          115 (89.84)             --                                           --                                          --                                        --

**Notes.**

*P* value \< 0.05.

A total of 26 ICU investigated patients died in hospital (13 were identified with candiduria and 13 did not). The death rate was significantly higher among candiduria patients than among those without candiduria (13/38 VS 13/128). For the 38 ICU candiduria subjects, eight received antifungal therapy, and two of them died; 30 did not receive antifungal treatment, and 11 of them died. There was no significant difference between the death rates of patients who received antifungal therapy and of those who did not (2/8 VS 11/30). One candiduria patient was clinically diagnosed as having candidemia with a positive blood culture of *Candida albicans*. This patient died within 15 days despite aggressive antifungal therapy.

Discussion
==========

The Sysmex UF-1000i is a fully automatic fluorescence cytometric urine analyzer capable of detecting various urine particles, including bacteria (BACT), red cells (RBCs), white cells (WBCs), yeast-like cells (YLCs), epithelial cells, casts, crystals, spermatozoa, small round cells and mucus ([@ref-6]). Several studies ([@ref-11]; [@ref-21]; [@ref-23]) have shown that the Sysmex UF-1000i analyzer can determine UTIs and candiduria in a simple manner with considerable quantification. Our data indicated that the sensitivity, specificity, PPV, and NPV were 61.7%, 84.1%, 88.6% and 66.3%, respectively, using a cutoff value of 84.6 YLCs/µL. According to a report from [@ref-11], the sensitivity, specificity, PPV and NPV of urine YLC counts for determining candiduria were 87.3%, 97.0%, 9.3% and 99.9%, respectively, with a cutoff value of ≥50 YLCs/µL. Compared to the present study, their study used a relatively low cutoff value and enrolled all YLC-negative subjects into the calculation, leading to a very low PPV. When determining the cutoff value, we only included the YLC-positive subjects in the calculation because the main question of the present study was whether positive YLC indicated candiduria.

The urinary tract is one of the most frequent sites for candida colonization, and the presence of candida in urine should not be ignored because candida colonization is a risk factor for the progress of invasive candidiasis (IC) ([@ref-20]; [@ref-7]). In our study, the general incidence of candiduria was 1.61% in hospitalized patients. Actually, according to limited data available, the candiduria incidence rates were varied from 0.77% to over 20% ([@ref-18]; [@ref-5]). Our result was comparable to a clinic-based retrospective and prospective study using culture assay conducted by [@ref-5]. Compared to study data regarding candiduria epidemiology in community settings, by which the candiduria rates were reported respectively as low as 0.4% ([@ref-11]) and 0.14% ([@ref-5]), our investigation result is much higher in hospitalized patients. This result indicates that the incidence of candiduria varied according to subject groups. *C. glabrata* and *C. tropicalis* were found more often than was *C. albicans*, agreeing with the trend of non-albicans Candida prevalence worldwide. Especially in the urinary tract, non-albicans Candida species were reported better-adapted to the environment ([@ref-30]). *C. glabrata* ([@ref-28]) and *C. tropicalis* ([@ref-29]) were identified as the most prevalent urinary tract Candida species in various studies.

Candiduria occurrence rates varied according to age groups. The incidence was 2.51% in patients older than 60 years and 3.41% in patients younger than 1 year, significantly higher than the overall incidence rate (1.61%). Older age is a classical risk factor for candiduria ([@ref-10]). In healthy babies, the urinary tract is generally considered to be clean and without candida colonization, while in NICU patients, particularly premature infants, candiduria and candidemia were not rare ([@ref-16]; [@ref-33]). Gender is another factor that may affect the candiduria incidence ([@ref-15]). In the present study, the candiduria incidence was significantly higher in females than in males. A possible explanation to this finding may be the common colonization of Candida in the urogenital tract or Candida vulvovaginitis in females ([@ref-5]; [@ref-19]).

To explore the correlation between underlying diseases and candiduria in hospitalized patients, the candiduria incidences in patients who were admitted to various wards were investigated. As expected, ICU patients showed the highest candiduria incidence (22.89%). Patients from nephrology (7.06%), geriatrics (5.66%), NICU (3.66%), neurosurgery (2.94%), hematology (2.78%) and oncology (2.60%) wards also showed considerably high candiduria rates. This result might imply that stays in the ICU, major surgery, very old/young age, diabetes, renal disease, malignancy and immunosuppressive therapy, in addition to gender, could be considered to be major risk factors for candiduria. For patients undergoing neurosurgery, whether a urinary catheter was used in the peri-operative period is very important for the development of candiduria ([@ref-19]). In the present study, all 274 patients undergoing head operations had a record of urinary catheter usage that might be a major cause of the high prevalence of candiduria in the neurosurgery ward.

In ICU patients, urinary catheterization appeared to be statistically significant risk factor. The presence of a catheter in the urinary tract was always an important factor associated with candiduria and various UTIs, as confirmed by many studies ([@ref-25]; [@ref-24]; [@ref-31]; [@ref-17]). Previous antibiotic therapy has been considered to be another important risk factor, playing a crucial role in the pathogenesis of candiduria ([@ref-35]). Excessive antibiotic use is widely recognized in the ICU patients we investigated (142 of 166 patients had a record of antibiotic therapy). The high prevalence of antibiotic use in ICU patients makes it difficult to clarify the role of antibiotic therapy in the prevalence of candiduria or Candida colonization in our report.

The total mortality rate for ICU candiduria patients was 34.21%, approximately three times higher than that of the non-candiduria patients. This figure is very close to the mortality rate reported by [@ref-2]. Antifungal treatment had no effect on the mortality of ICU candiduria patients in our investigation. It appears likely that candiduria is a "red flag" or marker for seriously ill patients who need particular attention to their indwelling devices or underlying disease but has no direct contribution to the high mortality. Although the connection between candiduria and candidemia has been reported by several groups ([@ref-27]), only one ICU candiduria patient was finally diagnosed as having candidemia by microbiological culture in this study.

The findings of this study have to be seen in light of some limitations. First, the epidemiological data are obtained from the Sysmex UF-1000i YLC parameter. The performance of YLC for candiduria screening is relatively low, which might bias the results of our overall and subgroup analyses. However, retrospectively investigating candiduria with YLC could greatly reduce the selection bias caused by target population, for the reason that urine culture is warranted only when the patient exhibits urinary tract infection symptoms in clinical practice, while urinalysis is performed as a routine examination on each patient. Second, the sample size for ICU patients is not big enough. Third, as a retrospective study, we only conduct follow-up evaluation for the outcome of ICU patients.

Conclusions
===========

To our knowledge, this is the first epidemiological study of candiduria with a large-scale investigated population conducted using the Sysmex UF-1000i urine analyzer. The incidence rate of candiduria in hospitalized patients was approximately 1.61% and varied according to age, gender and the wards where they were isolated. Presence of a catheter was the only independent risk factor in ICU patients. Antifungal therapy had no effect on the mortality of ICU candiduria patients, implying that candiduria was not directly associated with mortality.

Supplemental Information
========================
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###### Dataset of the present study

This dataset including 4 files named A, B, C and D. (A) indicates the urine YLC counts in patients admitted in internal wards; (B) indicates the urine YLC counts in patients admitted in surgery wards; (C) indicates the performance of YLCs in screening candiduria, based on which we draw the ROC curve and determined the YLC cut-off value. (D) indicates risk factors and outcome of ICU patients with/without candiduria, N means No, Y means Yes.

###### 

Click here for additional data file.
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